City

Clinical trials near Hamburg, Germany

Active studies with a listed research site in Hamburg, Germany.

20active studies

9recruiting now

25countries represented

229largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

ObesityCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Argentina, Australia72 locations

Novo Nordisk A/SSponsor

Updated 2026-08-27 · NCT07503210See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 4

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Chronic Kidney Disease(CKD)Condition

Dapagliflozin, SemaglutideTreatment

Denmark, Germany4 locations

Peter RossingSponsor

Updated 2025-11-20 · NCT07239570See eligibility →

Recruiting nowNot applicable

Hamburg City Health Study - a German Cohort Study

Coronary Heart Disease, StrokeCondition

Intervention not listedTreatment

Germany1 locations

Universitätsklinikum Hamburg-EppendorfSponsor

Updated 2019-05-02 · NCT03934957See eligibility →

Opening soonPhase 3

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Obesity, OverweightCondition

NNC0487-0111, SemaglutideTreatment

Argentina, Brazil120 locations

Novo Nordisk A/SSponsor

Updated 2026-03-12 · NCT07400107See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

Hypothalamic ObesityCondition

Setmelanotide, PlaceboTreatment

Canada, Germany28 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2026-08-10 · NCT05774756See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Semaglutide, Placebo (semaglutide)Treatment

Brazil, Bulgaria229 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT03811561See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingNot applicable

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

Asthma Bronchiale, Breast NeoplasmsCondition

gp-multitool.deTreatment

Germany1 locations

Universitätsklinikum Hamburg-EppendorfSponsor

Updated 2026-05-29 · NCT06831994See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingNot applicable

Early Genetic Identification of Obesity

Obesity, Childhood, HyperphagiaCondition

Genetic testing via blood collectionTreatment

Germany37 locations

Rolfs Consulting und Verwaltungs-GmbH (RCV)Sponsor

Updated 2025-09-29 · NCT06239064See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Hamburg, Germany

Current studies

Related cities